Webcasts Investor Day Meeting Today
VALLEY FORGE, Pa.--(BUSINESS WIRE)--Dec. 12, 2012--
AmerisourceBergen Corporation (NYSE: ABC) today will reaffirm its
previous fiscal year 2013 guidance at its Investor Day Meeting in New
York City. The Company is hosting a webcast of the meeting today
beginning at 12:30 pm Eastern Standard Time.
The Company continues to expect diluted earnings per share from
continuing operations in fiscal year 2013 to be in the range of $3.06 to
$3.16, an 11 percent to 14 percent increase over fiscal 2012. The
Company also continues to expect revenue growth in the 6 percent to 9
percent range; operating income growth in the 3 percent to 5 percent
range; and now expects an operating margin decline in the high single to
low double-digit basis points range; and free cash flow in the range of
$750 million to $850 million, which includes capital expenditures in the
$180 million range. Subject to market conditions, the Company expects to
spend at least $200 million to repurchase our common shares in fiscal
year 2013.
AmerisourceBergen will webcast its Investor Day Meeting today beginning
at 12:30 pm Eastern Standard Time through approximately 3:30 pm.
Participating in the meeting will be: Steven H. Collis, President and
Chief Executive Officer; Tim G. Guttman, Senior Vice President and Chief
Financial Officer; David W. Neu, President, AmerisourceBergen Drug
Corporation, James D. Frary, President, AmerisourceBergen Specialty
Group; Peyton R. Howell, President, Global Sourcing and Manufacturer
Relations. To access the live webcast, go to the Webcasts section on the
Investor Relations page at www.amerisourcebergen.com.
A replay of the webcast will be available for 30 days.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from niche
premium logistics and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With nearly $80 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 13,000 people. AmerisourceBergen is ranked #29 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations
governing the marketing, sale, purchase, and/or dispensing of
pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product
pricing or reimbursement policies, including under Medicaid and
Medicare; changes in regulatory or clinical medical guidelines and/or
labeling for the pharmaceutical products we distribute, including
certain anemia products; price inflation in branded pharmaceuticals and
price deflation in generics; greater or less than anticipated benefit
from launches of the generic versions of previously patented
pharmaceutical products; significant breakdown or interruption of our
information technology systems; our inability to realize the anticipated
benefits of the implementation of an enterprise resource planning (ERP)
system; success of integration, restructuring or systems initiatives;
interest rate and foreign currency exchange rate fluctuations; risks
associated with international business operations, including
non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery
laws and economic sanctions and import laws and regulations; economic,
business, competitive and/or regulatory developments outside of the
United States; changes and/or potential changes in Canadian provincial
legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing and service fees; the impact of
divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our
inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax laws or legislative
initiatives that could adversely affect our tax positions and/or our tax
liabilities or adverse resolution of challenges to our tax positions;
increased costs of maintaining, or reductions in our ability to
maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic,
business, competitive, legal, tax, regulatory and/or operational factors
affecting our business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on
Form 10-K for the fiscal year ended September 30, 2012 and elsewhere in
that report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act of 1934.
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Barbara A. Brungess,
610-727-7199
bbrungess@amerisourcebergen.com